Roche and GLYCART to discover new therapeutic antibodies

22-Sep-2004

Roche and GLYCART biotechnology today announced an agreement to discover next-generation therapeutic antibodies using GlycoMAbTM technology. Roche will have the option to develop and market worldwide all antibodies generated by GLYCART from an undisclosed product candidate. GLYCART will receive an upfront fee, research funding, milestone payments and royalties on product sales.

"We have rapidly generated GlycoMAbTM versions of Roche's antibody with dramatically enhanced potency, and we are pleased that after this initial technology evaluation, Roche has decided to license GlycoMAbTM," said Pablo Uma?a, PhD, CSO of GLYCART. Joël Jean-Mairet, PhD, CEO of GLYCART, added, "The significance of bringing our technology to a global antibody player such as Roche cannot be underestimated. Clearly, this collaboration will be invaluable to GLYCART in continuing to forge partnerships with the leading antibody companies."

"In the first quarter of this year, 49 percent of Roche's sales came from biotechnology products," explained Peter Hug, Roche's Global Head of Pharma Partnering. "To maintain and expand our leadership in the antibody market, and in disease areas such as oncology, Roche will continue to partner with excellent antibody companies such as GLYCART."

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous